Pharmacotherapy of Epilepsy
- 1 February 2011
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 25 (2) , 89-107
Abstract
This article discusses seven newly available antiepileptic drugs (AEDs) and agents in phase III development. Lacosamide, licensed as an adjunctive treatment for partial-onset seizures, primarily acts...Keywords
This publication has 119 references indexed in Scilit:
- Lacosamide in Painful Diabetic Neuropathy: An 18-Week Double-Blind Placebo-Controlled TrialThe Journal of Pain, 2009
- The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsyEpilepsy Research, 2009
- Efficacy and Safety of Lacosamide in Diabetic Neuropathic PainThe Clinical Journal of Pain, 2009
- Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2ABritish Journal of Pharmacology, 2008
- The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy menBritish Journal of Clinical Pharmacology, 2008
- Nervous system KV7 disorders: breakdown of a subthreshold brakeThe Journal of Physiology, 2008
- Likelihood of seizure remission in an adult population with refractory epilepsyAnnals of Neurology, 2007
- The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy malesBritish Journal of Clinical Pharmacology, 2007
- Molecular Targets for Antiepileptic Drug DevelopmentNeurotherapeutics, 2007
- Diverse mechanisms of antiepileptic drugs in the development pipelineEpilepsy Research, 2006